论文部分内容阅读
目的:探讨急性ST段抬高型心肌梗死的急诊药物选择与预后。方法:急性ST段抬高型心肌梗死患者50例分为治疗组与对照组各25例,对照组采用常规溶栓治疗,治疗组采用尿激酶溶栓治疗,治疗7天。结果:治疗后,治疗组的总有效率(96.0%)明显高于对照组(84.0%)(P<0.05)。所有患者治疗后随访3个月,治疗组的严重心衰、再发心绞痛、冠状动脉血运重建等总体心脏不良事件发生情况明显低于对照组(P<0.05)。结论:相对于传统溶栓,尿激酶溶栓治疗急性ST段抬高型心肌梗死能有效提高近远期疗效,值得在临床上推广应用。
Objective: To investigate the emergency drug selection and prognosis of acute ST-segment elevation myocardial infarction. Methods: Fifty patients with acute ST-segment elevation myocardial infarction were divided into treatment group and control group with 25 cases each. The control group was treated by conventional thrombolytic therapy. The treatment group was treated with urokinase thrombolysis for 7 days. Results: After treatment, the total effective rate (96.0%) in the treatment group was significantly higher than that in the control group (84.0%) (P <0.05). All patients were followed up for 3 months after treatment. The adverse cardiac events such as severe heart failure, recurrence of angina and coronary revascularization in the treatment group were significantly lower than those in the control group (P <0.05). Conclusion: Compared with traditional thrombolysis, urokinase thrombolytic therapy for acute ST-segment elevation myocardial infarction can effectively improve the short-term and long-term efficacy, which is worth popularizing in clinic.